Journal of Psychopharmacology
May 1, 2007
Karsten Heekeren, Anna Neukirch, Jörg Daumann et al.
49 citations
Patients with schizophrenia exhibit diminished prepuLse inhibition (PPI) of the acoustic startle reflex and deficits in the attentional moduLation of PPI. Pharmacological challenges with hallucinogens are used as models for psychosis in both humans and animals. RemarkabLy, in contrast to the findings in schizophrenic patients and in animal hallucinogen modeLs of psychosis, previous studies with...
Pharmacopsychiatry
September 1, 2005
Euphrosyne Gouzoulis‐mayfrank, Anna Neukirch, Karsten Heekeren
2 citations
Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often considered as a more appropriate model of psychosis than the state induced by serotonergic hallucinogens such as lysergic acid (LSD), psilocybin and dimethyltryptamine (DMT). However, so far, this question has...
American Journal of Therapeutics
Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al.
10 citations
Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal...
Clinical Neuropharmacology
Wei Xie, Le Wang, Zhe Peng et al.
6 citations
This study aimed to investigate the effects of preoperative low-dose esketamine and dexmedetomidine nasal administration on the incidence of postoperative emergence delirium in children undergoing fiber bronchoscopy. A total of 129 patients, of any gender, aged 1 to 6 years, with ASA grades I and II, who were scheduled for fiber bronchoscopy, were randomly divided into three groups (n = 43)...
Ella Daly, Jaskaran Singh, Maggie Fedgchin et al.
Background: Intravenous ketamine and esketamine (ESK) produce rapid antidepressant action in treatment-resistant depression (TRD) patients, however dose response is not known. Study assessed efficacy, dose response and safety of intranasal ESK and ability to sustain response with gradual tapering of treatment frequency. Methods: In the Panel A (conducted in USA and Belgium) of this...
Jun Jing, Meng-Ying Zhang, Wei-hong Yin et al.
preprint
Abstract Objective To observe the effects of esketamine on postoperative depression and pain indicators in individuals undergoing total laparoscopic hysterectomy. Methods 135 patients undegoing total laparoscopic hysterectomy were recruited and randomly allocated to three groups. Finally, a total of 127 patients were selected into the statistical analysis, with the final grouping information as...
Muyan Zuo, Yaozu Li, John P Williams et al.
preprint
Purpose: Depression combined with insomnia is a complex bidirectional relationship that is more difficult to treat versus a single disorder, and there is a lack of effective treatments available. In this study, we carried out a novel way to simultaneously intervene in depression combined with insomnia and examined functional magnetic resonance imaging (fMRI) to help further elucidate the...
Ling Qiu, Xuhui Chen, Fu Jia et al.
preprint
Abstract Objective Patients with Postherpetic Neuralgia (PHN) often exhibit depressive-like symptoms, significantly impacting their quality of life. Esketamine, known for its analgesic properties, has also been recognized for its rapid antidepressant effects. However, its efficacy in the treatment of PHN requires further exploration. This study aims to evaluate the impact of intravenous...
Shurong Li, Zhifang Zhuo, Renwei Li et al.
preprint
Abstract Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section....
Hannah Tramontano, Jeffrey Fetter, Mohamed Wagdy ElSayed
preprint
Background: Borderline Personality Disorder (BPD) affects 1.35% of the population and is frequently comorbid with Major Depressive Disorder (MDD), which is frequently treatment-resistant (TRD). Patients with comorbid illness have worse treatment outcomes and functional impairment. Esketamine could ameliorate symptoms of both illnesses. Methods: We conducted a retrospective chart review of...